{"id":25032,"date":"2026-04-09T17:58:10","date_gmt":"2026-04-09T15:58:10","guid":{"rendered":"https:\/\/www.korea-certification.com\/?p=25032"},"modified":"2026-04-09T17:58:39","modified_gmt":"2026-04-09T15:58:39","slug":"jw-pharmaceutical-gains-korean-rights-to-next-generation-glp-1-therapy-in-strategic-licensing-deal","status":"publish","type":"post","link":"https:\/\/www.korea-certification.com\/en\/jw-pharmaceutical-gains-korean-rights-to-next-generation-glp-1-therapy-in-strategic-licensing-deal\/","title":{"rendered":"JW Pharmaceutical Gains Korean Rights to Next-Generation GLP-1 Therapy in Strategic Licensing Deal"},"content":{"rendered":"\n

JW Pharmaceutical has entered into a licensing agreement with China-based Gan & Lee Pharmaceuticals to obtain exclusive rights in Korea for bofanglutide, an advanced GLP-1 receptor agonist. Under the terms of the deal, JW Pharmaceutical will oversee clinical development, regulatory submissions, and commercialization within the Korean market, while Gan & Lee will supply the necessary data and documentation to support investigational new drug applications and product approvals. The total agreement value may reach $81.1 million, including an upfront payment of $5 million and additional milestone-based payments linked to approvals across multiple indications. Medical products usually require MFDS certification<\/strong><\/a> in order to be approved for import and sale in Korea.<\/p>\n\n\n\n

<\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

<\/p>\n\n\n\n

The drug has demonstrated promising outcomes in clinical studies, including a Phase 2b trial where patients achieved an average weight reduction of 17.3 percent over 30 weeks with biweekly administration. JW Pharmaceutical plans to initiate Phase 3 trials in Korea later this year, targeting obesity and type 2 diabetes. The partnership aligns with growing global and regional demand for GLP-1 therapies, with the Asia-Pacific market projected to expand significantly in the coming years. Both companies emphasized that the collaboration will support the advancement of innovative treatments and broaden access to new therapeutic options in Korea.<\/p>\n\n\n\n

Feel free to contact us any time if you need assistance or have any questions regarding Korean certifications like KC<\/strong><\/a>, KC EMC<\/strong><\/a>, KCs<\/strong><\/a>, KCs for explosion safety products<\/strong><\/a>, MFDS certification<\/strong><\/a> for medical products or KGS factory registration<\/strong><\/a>.<\/p>\n\n\n\n

Tel. Europe: +49-69-271 37 69 259
<\/strong>Tel. US: +1 773 654-2673<\/strong><\/strong><\/p>\n\n\n\n

Email: info@korea-certification.com<\/strong><\/a><\/strong><\/p>\n\n\n\n

For more information you can download our free brochure “Korea Certification Made Easy – The Booklet<\/strong><\/a>“.<\/p>\n","protected":false},"excerpt":{"rendered":"

JW Pharmaceutical has entered into a licensing agreement with China-based Gan & Lee Pharmaceuticals to obtain exclusive rights in Korea for bofanglutide, an advanced GLP-1 receptor agonist. Under the terms of the deal, JW Pharmaceutical will oversee clinical development, regulatory submissions, and commercialization within the Korean market, while Gan & Lee will supply the necessary […]<\/p>\n","protected":false},"author":4,"featured_media":25033,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[106],"tags":[],"acf":[],"yoast_head":"\nJW Pharmaceutical Gains Korean Rights to Next-Generation GLP-1 Therapy in Strategic Licensing Deal<\/title>\n<meta name=\"description\" content=\"JW Pharmaceutical secures exclusive Korean rights to a next-generation GLP-1 drug. The deal with Gan & Lee supports development, approval, and commercialization of innovative therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.korea-certification.com\/en\/jw-pharmaceutical-gains-korean-rights-to-next-generation-glp-1-therapy-in-strategic-licensing-deal\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"JW Pharmaceutical Gains Korean Rights to Next-Generation GLP-1 Therapy in Strategic Licensing Deal\" \/>\n<meta property=\"og:description\" content=\"JW Pharmaceutical secures exclusive Korean rights to a next-generation GLP-1 drug. The deal with Gan & Lee supports development, approval, and commercialization of innovative therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.korea-certification.com\/en\/jw-pharmaceutical-gains-korean-rights-to-next-generation-glp-1-therapy-in-strategic-licensing-deal\/\" \/>\n<meta property=\"og:site_name\" content=\"MPR Korea Certification\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-09T15:58:10+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-09T15:58:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.korea-certification.com\/wp-content\/uploads\/Medical-products-1-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Louis Gogger\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Louis Gogger\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.korea-certification.com\/en\/jw-pharmaceutical-gains-korean-rights-to-next-generation-glp-1-therapy-in-strategic-licensing-deal\/\",\"url\":\"https:\/\/www.korea-certification.com\/en\/jw-pharmaceutical-gains-korean-rights-to-next-generation-glp-1-therapy-in-strategic-licensing-deal\/\",\"name\":\"JW Pharmaceutical Gains Korean Rights to Next-Generation GLP-1 Therapy in Strategic Licensing Deal\",\"isPartOf\":{\"@id\":\"https:\/\/www.korea-certification.com\/en\/#website\"},\"datePublished\":\"2026-04-09T15:58:10+00:00\",\"dateModified\":\"2026-04-09T15:58:39+00:00\",\"author\":{\"@id\":\"https:\/\/www.korea-certification.com\/en\/#\/schema\/person\/4f5cd923141741b7fe96721b17c464bf\"},\"description\":\"JW Pharmaceutical secures exclusive Korean rights to a next-generation GLP-1 drug. The deal with Gan & Lee supports development, approval, and commercialization of innovative therapies.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.korea-certification.com\/en\/jw-pharmaceutical-gains-korean-rights-to-next-generation-glp-1-therapy-in-strategic-licensing-deal\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.korea-certification.com\/en\/jw-pharmaceutical-gains-korean-rights-to-next-generation-glp-1-therapy-in-strategic-licensing-deal\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.korea-certification.com\/en\/jw-pharmaceutical-gains-korean-rights-to-next-generation-glp-1-therapy-in-strategic-licensing-deal\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.korea-certification.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"JW Pharmaceutical Gains Korean Rights to Next-Generation GLP-1 Therapy in Strategic Licensing Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.korea-certification.com\/en\/#website\",\"url\":\"https:\/\/www.korea-certification.com\/en\/\",\"name\":\"MPR Korea Certification\",\"description\":\"Ihr Experte f\u00fcr Korea-Zertifizierungen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.korea-certification.com\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.korea-certification.com\/en\/#\/schema\/person\/4f5cd923141741b7fe96721b17c464bf\",\"name\":\"Louis Gogger\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.korea-certification.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/www.korea-certification.com\/wp-content\/uploads\/Louis_Gogger-4-3-2-1-150x150.jpg\",\"contentUrl\":\"https:\/\/www.korea-certification.com\/wp-content\/uploads\/Louis_Gogger-4-3-2-1-150x150.jpg\",\"caption\":\"Louis Gogger\"},\"description\":\"About the author: Louis Gogger is Managing Director of MPR International GmbH. Publisher: MPR International GmbH Tel.: +49 69 271 37 69 261 E-Mail: info@korea-certification.com Web: www.korea-certification.com\",\"url\":\"https:\/\/www.korea-certification.com\/en\/author\/julian-busch\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"JW Pharmaceutical Gains Korean Rights to Next-Generation GLP-1 Therapy in Strategic Licensing Deal","description":"JW Pharmaceutical secures exclusive Korean rights to a next-generation GLP-1 drug. The deal with Gan & Lee supports development, approval, and commercialization of innovative therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.korea-certification.com\/en\/jw-pharmaceutical-gains-korean-rights-to-next-generation-glp-1-therapy-in-strategic-licensing-deal\/","og_locale":"en_US","og_type":"article","og_title":"JW Pharmaceutical Gains Korean Rights to Next-Generation GLP-1 Therapy in Strategic Licensing Deal","og_description":"JW Pharmaceutical secures exclusive Korean rights to a next-generation GLP-1 drug. The deal with Gan & Lee supports development, approval, and commercialization of innovative therapies.","og_url":"https:\/\/www.korea-certification.com\/en\/jw-pharmaceutical-gains-korean-rights-to-next-generation-glp-1-therapy-in-strategic-licensing-deal\/","og_site_name":"MPR Korea Certification","article_published_time":"2026-04-09T15:58:10+00:00","article_modified_time":"2026-04-09T15:58:39+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/www.korea-certification.com\/wp-content\/uploads\/Medical-products-1-1.jpg","type":"image\/jpeg"}],"author":"Louis Gogger","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Louis Gogger","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.korea-certification.com\/en\/jw-pharmaceutical-gains-korean-rights-to-next-generation-glp-1-therapy-in-strategic-licensing-deal\/","url":"https:\/\/www.korea-certification.com\/en\/jw-pharmaceutical-gains-korean-rights-to-next-generation-glp-1-therapy-in-strategic-licensing-deal\/","name":"JW Pharmaceutical Gains Korean Rights to Next-Generation GLP-1 Therapy in Strategic Licensing Deal","isPartOf":{"@id":"https:\/\/www.korea-certification.com\/en\/#website"},"datePublished":"2026-04-09T15:58:10+00:00","dateModified":"2026-04-09T15:58:39+00:00","author":{"@id":"https:\/\/www.korea-certification.com\/en\/#\/schema\/person\/4f5cd923141741b7fe96721b17c464bf"},"description":"JW Pharmaceutical secures exclusive Korean rights to a next-generation GLP-1 drug. The deal with Gan & Lee supports development, approval, and commercialization of innovative therapies.","breadcrumb":{"@id":"https:\/\/www.korea-certification.com\/en\/jw-pharmaceutical-gains-korean-rights-to-next-generation-glp-1-therapy-in-strategic-licensing-deal\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.korea-certification.com\/en\/jw-pharmaceutical-gains-korean-rights-to-next-generation-glp-1-therapy-in-strategic-licensing-deal\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.korea-certification.com\/en\/jw-pharmaceutical-gains-korean-rights-to-next-generation-glp-1-therapy-in-strategic-licensing-deal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.korea-certification.com\/en\/"},{"@type":"ListItem","position":2,"name":"JW Pharmaceutical Gains Korean Rights to Next-Generation GLP-1 Therapy in Strategic Licensing Deal"}]},{"@type":"WebSite","@id":"https:\/\/www.korea-certification.com\/en\/#website","url":"https:\/\/www.korea-certification.com\/en\/","name":"MPR Korea Certification","description":"Ihr Experte f\u00fcr Korea-Zertifizierungen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.korea-certification.com\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.korea-certification.com\/en\/#\/schema\/person\/4f5cd923141741b7fe96721b17c464bf","name":"Louis Gogger","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.korea-certification.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/www.korea-certification.com\/wp-content\/uploads\/Louis_Gogger-4-3-2-1-150x150.jpg","contentUrl":"https:\/\/www.korea-certification.com\/wp-content\/uploads\/Louis_Gogger-4-3-2-1-150x150.jpg","caption":"Louis Gogger"},"description":"About the author: Louis Gogger is Managing Director of MPR International GmbH. Publisher: MPR International GmbH Tel.: +49 69 271 37 69 261 E-Mail: info@korea-certification.com Web: www.korea-certification.com","url":"https:\/\/www.korea-certification.com\/en\/author\/julian-busch\/"}]}},"_links":{"self":[{"href":"https:\/\/www.korea-certification.com\/en\/wp-json\/wp\/v2\/posts\/25032"}],"collection":[{"href":"https:\/\/www.korea-certification.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.korea-certification.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.korea-certification.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.korea-certification.com\/en\/wp-json\/wp\/v2\/comments?post=25032"}],"version-history":[{"count":2,"href":"https:\/\/www.korea-certification.com\/en\/wp-json\/wp\/v2\/posts\/25032\/revisions"}],"predecessor-version":[{"id":25038,"href":"https:\/\/www.korea-certification.com\/en\/wp-json\/wp\/v2\/posts\/25032\/revisions\/25038"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.korea-certification.com\/en\/wp-json\/wp\/v2\/media\/25033"}],"wp:attachment":[{"href":"https:\/\/www.korea-certification.com\/en\/wp-json\/wp\/v2\/media?parent=25032"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.korea-certification.com\/en\/wp-json\/wp\/v2\/categories?post=25032"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.korea-certification.com\/en\/wp-json\/wp\/v2\/tags?post=25032"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}